Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) i

N. C. Te Grootenhuis, A. G.J. Van Der Zee, H. C. Van Doorn, J. Van Der Velden, I. Vergote, V. Zanagnolo, P. J. Baldwin, K. N. Gaarenstroom, E. B. Van Dorst, J. W. Trum, B. F.M. Slangen, I. B. Runnebaum, K. Tamussino, R. H. Hermans, D. M. Provencher, G. H. De Bock, J. A. De Hullu, M. H.M. Oonk

Research output: Contribution to journalArticleAcademicpeer-review

209 Citations (Scopus)


Objective. In 2008 GROINSS-V-I, the largest validation trial on the sentinel node (SN) procedure in vulvar cancer, showed that application of the SN-procedure in patients with early-stage vulvar cancer is safe. The current study aimed to evaluate long-term follow-up of these patients regarding recurrences and survival. Methods. From2000 until 2006 GROINSS-V-I included 377 patientswith unifocal squamous cell carcinoma of the vulva (T1,<4 cm), who underwent the SN-procedure. Only in case of SN metastases an inguinofemoral lymphadenectomy was performed. For the present study follow-up was completed until March 2015. Results. Themedian follow-up was 105 months (range 0179). The overall local recurrence ratewas 27.2% at 5 years and 39.5% at 10 years after primary treatment, while for SN-negative patients 24.6% and 36.4%, and for SN-positive patients 33.2% and 46.4% respectively (p = 0.03). In 39/253 SN-negative patients (15.4%) an inguinofemoral lymphadenectomy was performed, because of a local recurrence. Isolated groin recurrence rate was 2.5% for SN-negative patients and 8.0% for SN-positive patients at 5 years. Disease-specific 10-year survival was 91% for SN-negative patients compared to 65% for SN-positive patients (p < .0001). For all patients, 10-year disease-specific survival decreased from 90% for patients without to 69% for patientswith a local recurrence (p < .0001).

Original languageEnglish
Pages (from-to)8-14
Number of pages7
JournalGynecologic Oncology
Issue number1
Publication statusPublished - 1 Jan 2016


  • Long-term follow-up
  • Sentinel node
  • Vulvar cancer

Cite this